Sakigake Designation: Priority Review and Early Consultation for Innovative Devices

1. Key takeaways

Sakigake designation, the scheme for pioneering medical devices, is Japan’s acceleration mechanism for products with outstanding innovation that address unmet medical needs. Its core value lies in priority review and intensive early consultation during development. The priority review processing-period target is 10 months, and PMDA’s disclosed FY2023 80th-percentile performance is 8.7 months. GRZAN’s judgment for Chinese innovative devices: the greater value of Sakigake lies in the early consultation, not merely in speed.

• The acceleration mechanism’s statutory anchor is the priority review provision of Article 23-2-5 of the PMD Act.
• Caution on numbering: paragraph numbering in Article 23-2-5 was rearranged by Act No. 37 of 2025, promulgated on 21 May 2025; confirm the current paragraph on e-Gov before citation.
• Act No. 37 of 2025 added to Article 23-2-5 a duty to publicize when the Minister grants approval after priority review.
• PMDA’s Profile of Services states the priority review target of 10 months and discloses FY2019 to FY2023 80th-percentile results of 7.3, 8.4, 8.9, 8.8 and 8.7 months.
• GRZAN’s assessment: for companies without Japanese clinical experience, the design-stage alignment with reviewers is worth more than the months saved.
• The practical reading of the five-year series is that the priority review band is both shorter and more stable than the standard review band, which is what makes schedule commitments under Sakigake defensible in a way that standard review commitments are not.

2. Legal basis

Priority review and publication. Article 23-2-5 of the PMD Act contains the provisions on approval, priority review and publication. Note on citation: the paragraph numbering of this article was rearranged by Act No. 37 of 2025, promulgated on 21 May 2025; confirm the specific paragraph against the current e-Gov text before citing it.

The 2025 amendment. In the amended text of Act No. 37 of 2025, Article 23-2-5 adds the provision that when the Minister of Health, Labour and Welfare conducts the review or investigation with priority and grants the approval under paragraph (1), the Minister is to publicize that fact. This publication duty gives the application of priority review external verifiability.

Performance data. PMDA’s Profile of Services states the priority review processing-period target of 10 months and discloses the FY2019 to FY2023 80th-percentile results as 7.3, 8.4, 8.9, 8.8 and 8.7 months respectively.

Consultation framework. PMDA’s consultation services, including pre-submission consultations and development-phase consultations, are the procedural vehicle through which Sakigake designation and its early guidance operate.

Current legal corpus. Act No. 145 of 1960 (the PMD Act).

3. Expert insights

The statutory anchor of acceleration is priority review plus publication. Sakigake designation itself is an administrative-operation scheme; its footing in the statute is the priority review provision of Article 23-2-5. Act No. 37 of 2025 went further and made explicit that when the Minister grants approval after priority review, the fact is to be publicized. That publication duty makes the application of priority review externally observable, which in turn disciplines the institution’s own conduct of the scheme. When advising clients, GRZAN uses the publication record as evidence of how the mechanism behaves in practice for comparable items. This converts what used to be anecdote-based benchmarking into an evidence check: the claimed acceleration, the actual grants and the items concerned can all be traced against the publicized record before the client commits development resources to the route.

Performance data are more predictive than targets. PMDA has disclosed 80th-percentile figures for five consecutive years, with priority review moving from 7.3 months in FY2019 to 8.7 months in FY2023, a narrower band than standard review. For companies that must commit launch dates externally, anchoring on the performance range is safer than quoting the target value. The five-year series also shows the direction of drift, which a single target number cannot; any external commitment should carry a schedule buffer aligned to the observed upper edge.

Early guidance is the scarcer resource. The consultation priority that comes with Sakigake designation lets the developer align endpoints and sample size with the reviewers at the trial-design stage. For Chinese companies without Japanese clinical experience, this single alignment is often worth more than the months cut from review, because it directly reduces post-submission demands for supplementary studies. The alignment itself is perishable: once the dossier is complete, the main benefit of the scheme has already been forfeited, which is why GRZAN urges assessment at the development stage rather than after. In project terms, the consultation slot should be planned the way a pivotal study is planned, with the questions prepared in advance and the outcomes written into the protocol before the dossier draft begins.

4. Practical recommendations

• Request the feasibility assessment early in development, not after the dossier is complete; the value of Sakigake concentrates in the development phase.
• Prepare a two-pillar argument covering innovation and unmet medical need, each argued against the current Japanese clinical situation rather than global data.
• Treat consultation records as the written basis for the later submission; agreements on trial design reached with PMDA should be documented for citation at review.
• Verify the paragraph number of the priority review provision against the current e-Gov text before citation, because the 2025 amendment moved the numbering.
• Anchor external launch commitments on the FY2019 to FY2023 performance range, not on the target value alone.

5. Verification checklist

• □ Was the feasibility assessment for Sakigake designation started early in development?
• □ Are the innovation and unmet-need arguments each directed at the Japanese clinical situation?
• □ Is there a written record of the consensus reached in PMDA consultations?
• □ When citing the priority review provision of Article 23-2-5, has the paragraph number been checked against the current e-Gov text?
• □ Do external launch commitments reference the FY2019 to FY2023 performance range rather than only the target value?

Regulatory information verified as at 29 October 2026. Legal texts follow the current provisions published on e-Gov and the notices issued by MHLW and PMDA, and must be rechecked after amendment or repeal. Time limits and procedural details reflect the official position on that date; content marked practical estimate has no legal effect.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, in-country representative and local testing support for the Japanese market. Our team manages PMDA premarket submissions and notification procedures, coordinates clinical evidence, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com